Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Status: RecruitingPhase: Phase 3Diagnosis: Multiple MyelomaNCT ID: NCT01734928
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID:
The purpose of this study is to compare the efficacy of the combination of Pomalidomide, Bortezomib and Dexamethasone to the combination of Bortezomib and Dexamethasone in patients with relapsed/refractory multiple myeloma. This study will also assess how safe the combination of Pomalidomide, Bortezomib and Dexamethasone is compared to the combination of Bortezomib and Dexamethasone
Conducting Institutions: Beth-Israel Deaconess Medical Center, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital
Overall PI: Jacalyn Rosenblatt, MD,
Beth Israel Deaconess Medical Center
Site-responsible Investigators: Paul Richardson, MD,
Dana-Farber Cancer InstituteAndrew Yee, MD,
Massachusetts General Hospital
Contacts: Beth-Israel Deaconess Medical Center:
Cancer Trials Call Center, 617-667-3060Dana-Farber Cancer Institute:
Deborah Doss, 617-632-5672,
email@example.comMassachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100